SG11201403324TA - Improved processes for preparing peptide conjugates and linkers - Google Patents

Improved processes for preparing peptide conjugates and linkers

Info

Publication number
SG11201403324TA
SG11201403324TA SG11201403324TA SG11201403324TA SG11201403324TA SG 11201403324T A SG11201403324T A SG 11201403324TA SG 11201403324T A SG11201403324T A SG 11201403324TA SG 11201403324T A SG11201403324T A SG 11201403324TA SG 11201403324T A SG11201403324T A SG 11201403324TA
Authority
SG
Singapore
Prior art keywords
linkers
peptide conjugates
improved processes
preparing peptide
preparing
Prior art date
Application number
SG11201403324TA
Other languages
English (en)
Inventor
Javier Magano
Mark Thomas Maloney
Olivier J Marcq
Durgesh Vasant Nadkarni
Mark John Pozzo
Jr John Joseph Teixeira
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201403324TA publication Critical patent/SG11201403324TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201403324TA 2011-12-20 2012-12-10 Improved processes for preparing peptide conjugates and linkers SG11201403324TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161578150P 2011-12-20 2011-12-20
PCT/IB2012/057142 WO2013093705A2 (en) 2011-12-20 2012-12-10 Improved processes for preparing peptide conjugates and linkers

Publications (1)

Publication Number Publication Date
SG11201403324TA true SG11201403324TA (en) 2014-07-30

Family

ID=47559605

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201403324TA SG11201403324TA (en) 2011-12-20 2012-12-10 Improved processes for preparing peptide conjugates and linkers

Country Status (14)

Country Link
US (1) US9352050B2 (de)
EP (1) EP2793950A2 (de)
JP (1) JP2013139440A (de)
KR (1) KR20140127224A (de)
CN (1) CN104125838B (de)
AU (1) AU2012356204B2 (de)
BR (1) BR112014015141A2 (de)
CA (1) CA2860109C (de)
HK (1) HK1203150A1 (de)
IL (1) IL233286A0 (de)
MX (1) MX2014007500A (de)
RU (1) RU2014124989A (de)
SG (1) SG11201403324TA (de)
WO (1) WO2013093705A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US573375A (en) 1896-12-15 Folding umbrella
JPH04178355A (ja) * 1990-11-14 1992-06-25 Hodogaya Chem Co Ltd ３，５―ジフルオロアニリンの製造方法
CA2048078A1 (en) * 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
EP0710644B1 (de) * 1994-11-03 1997-09-24 Bayer Ag Verfahren zur Herstellung von 4,6-Diaminoresorcin
JP2000506119A (ja) * 1996-02-15 2000-05-23 ノボ ノルディスク アクティーゼルスカブ ポリペプチドのコンジュゲーション
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
EP1218413A4 (de) 1999-09-27 2005-06-15 Univ California Antikörpermanipulation zur irreversiblen bindung
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
CN1253468C (zh) * 2001-11-12 2006-04-26 彭博 具有抗骨质疏松作用的雌激素－生长激素释放肽缀合物
JP5167473B2 (ja) * 2005-03-03 2013-03-21 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管新生化合物
JP4897050B2 (ja) * 2006-11-10 2012-03-14 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗血管形成化合物
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds

Also Published As

Publication number Publication date
US9352050B2 (en) 2016-05-31
WO2013093705A2 (en) 2013-06-27
AU2012356204A1 (en) 2014-07-10
CA2860109A1 (en) 2013-06-27
CA2860109C (en) 2016-08-09
KR20140127224A (ko) 2014-11-03
EP2793950A2 (de) 2014-10-29
JP2013139440A (ja) 2013-07-18
CN104125838A (zh) 2014-10-29
BR112014015141A2 (pt) 2020-10-27
IL233286A0 (en) 2014-08-31
US20150031108A1 (en) 2015-01-29
AU2012356204B2 (en) 2016-02-04
MX2014007500A (es) 2014-07-28
CN104125838B (zh) 2016-12-14
HK1203150A1 (en) 2015-10-23
WO2013093705A3 (en) 2013-08-15
RU2014124989A (ru) 2016-02-10

Similar Documents

Publication Publication Date Title
HK1243427A1 (zh) 治療肽
HK1213773A1 (zh) 用於蛋白質藥物偶聯物的支鏈聯接體
HK1208186A1 (en) Drug protein conjugates
HK1208187A1 (en) Drug protein conjugates
IL233280A0 (en) Cell-penetrating peptides
EP2624845A4 (de) Verbesserte msc-präparate
GB201003922D0 (en) Conjugation process
GB201012651D0 (en) Peptides
EP2605786A4 (de) Therapeutische peptide
EP2575887A4 (de) Optimierte arzneimittelkonjugate
EP2753641A4 (de) Neuroprotektive zellpenetrierende peptide
ZA201307169B (en) Neuroprotective peptides
IL214257A0 (en) Peptides for vaccine
GB201115910D0 (en) Peptides
EP2591799A4 (de) Krebspeptid-impfstoff
EP2627674A4 (de) Peptide auf egfr-basis
EP2793918A4 (de) Hdc-sign-bindende peptide
EP2786145A4 (de) Melittin-peptidkonjugate und diese verwendende verfahren
EP2511371A4 (de) Peptidantikörper gegen krebs und mortalin
HK1203150A1 (en) Improved processes for preparing peptide conjugates and linkers
EP2714717A4 (de) Phoenixinpeptide
GB201001624D0 (en) Peptides for vaccine
IL228354A0 (en) Neuroprotective peptides
GB201007678D0 (en) Tripeptide conjugates
GB201010058D0 (en) Peptide vaccine